Overview

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Connect Biopharmaceuticals, Ltd.
Collaborators:
Nucleus Network Ltd
Tigermed Consulting Co., Ltd